Acadia Pharmaceuticals, Inc. (ACAD) Reports In-Line Q3 EPS Loss of $0.10
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $25.50 --0%
Revenue Growth %: +11.9%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
CCEL, FNGR, FAST, More
Revenue Growth %: +11.9%
Financial Fact:
Net loss per common share, basic and diluted: -0.61
Today's EPS Names:
CCEL, FNGR, FAST, More
Join SI Premium – FREE
Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) reported Q3 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $584 thousand versus the consensus estimate of $500 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AngioDynamics (ANGO) Tops Q4 EPS by 2c ; Offers Guidance
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Acadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
